Therapeutics MD Reports Improved Financials for FY 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Source: seekingalpha
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXMD
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
See More
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
See More
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
See More
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
See More
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
See More
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
See More
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
See More
